A modified vimentin histological score helps recognize pulmonary sarcomatoid carcinoma in small biopsy samples

Anticancer Research

Volumn 32, Issue 4, 2012, Pages 1463-1473

  Pelosi, Giuseppe ^a,b   Melotti, Flavia ^a   Cavazza, Alberto ^c   Rossi, Giulio ^d   Maisonneuve, Patrick ^e   Graziano, Paolo ^f   Barbareschi, Mattia ^g   Nakatani, Yukio ^h   Papotti, Mauro ⁱ  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c S MARIA NUOVA HOSPITAL   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^f SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^g SANTA CHIARA HOSPITAL   (Italy)

^h CHIBA UNIVERSITY HOSPITAL   (Japan)

ⁱ UNIVERSITY OF TURIN   (Italy)

Author keywords

Biopsy; Cytokeratins; Immunohistochemistry; Lung cancer; Morphology; p40; p63; Pulmonary sarcomatoid carcinoma; TTF1; Vimentin

Indexed keywords

VIMENTIN;

ADULT; AGED; ARTICLE; CARCINOSARCOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; LUNG BLASTOMA; LUNG NON SMALL CELL CANCER; LUNG SARCOMA; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; TISSUE SECTION; TUMOR DIFFERENTIATION; TUMOR VOLUME;

BIOPSY; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; SARCOMA; TUMOR MARKERS, BIOLOGICAL; VIMENTIN;

EID: 84859958042     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Travis W, Brambilla E, Muller-Hermelink H and Harris C. Tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 344, 2004.
2. Blaukovitsch M, Halbwedl I, Kothmaier H, Gogg-Kammerer M and Popper HH: Sarcomatoid carcinomas of the lung - Are these histogenetically heterogeneous tumors? Virchows Arch 449: 455-461, 2006. (Pubitemid 44451320)
3. Pelosi G, Sonzogni A, De Pas T, Galetta D, Veronesi G, Spaggiari L, Manzotti M, Fumagalli C, Bresaola E, Nappi O, Viale G and Rosai J: Review article: pulmonary sarcomatoid carcinomas: a practical overview. Int J Surg Pathol 18: 103-120, 2010.
4. Pelosi G, Fraggetta F, Nappi O, Pastorino U, Maisonneuve P, Pasini F, Iannucci A, Solli P, Musavinasab H, De Manzoni G, Terzi A and Viale G: Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth and tumor cell motility: a clinicopathological and immunohistochemical study of 31 cases. Am J Surg Pathol 27: 1203-1215, 2003. (Pubitemid 37040582)
5. Rossi G, Cavazza A, Sturm N, Migaldi M, Facciolongo N, Longo L, Maiorana A and Brambilla E: Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases. Am J Surg Pathol 27: 311-324, 2003. (Pubitemid 36245796)
6. Dacic S, Finkelstein S, Sasatomi E, Swalsky P and Yousem S: Molecular pathogenesis of pulmonary carcinosarcoma as determined by microdissection-based allelotyping. Am J Surg Pathol 26: 510-516, 2002. (Pubitemid 34280126)
7. Nakatani Y, Miyagi Y, Takemura T, Oka T, Yokoi T, Takagi M, Yokoyama S, Kashima K, Hara K, Yamada T, Nozawa A, Inayama Y, Sakamoto K, Ogawa N, Kitamura H, Resl M, Cho SH, Koss MN and Mark EJ: Aberrant nuclear/cytoplasmic localization and gene mutation of beta-catenin in classic pulmonary blastoma: beta-catenin immunostaining is useful for distinguishing between classic pulmonary blastoma and a blastomatoid variant of carcinosarcoma. Am J Surg Pathol 28: 921-927, 2004. (Pubitemid 38856849)
8. Mochizuki T, Ishii G, Nagai K, Yoshida J, Nishimura M, Mizuno T, Yokose T, Suzuki K and Ochiai A: Pleomorphic carcinoma of the lung: clinicopathologic characteristics of 70 cases. Am J Surg Pathol 32: 1727-1735, 2008.
9. Pelosi G, Scarpa A, Manzotti M, Veronesi G, Spaggiari L, Fraggetta F, Nappi O, Benini E, Pasini F, Antonello D, Iannucci A, Maisonneuve P and Viale G: K-ras gene mutational analysis supports a monoclonal origin of biphasic pleomorphic carcinoma of the lung. Mod Pathol 17: 538-546, 2004. (Pubitemid 38868420)
10. Wick M, Ritter J and Humphrey P: Sarcomatoid carcinomas of the lung. A clinicopathological review. Am J Clin Pathol 108: 40-53, 1997. (Pubitemid 27276512)
11. Cates JM, Dupont WD, Barnes JW, Edmunds HS, Fasig JH, Olson SJ and Black CC: Markers of epithelial mesenchymal transition and epithelial differentiation in sarcomatoid carcinoma: utility in the differential diagnosis with sarcoma. Appl Immunohistochem Mol Morphol 16: 251-262, 2008. (Pubitemid 351589558)
12. Ivaska J: Vimentin: Central hub in EMT induction? Small Gtpases 2: 51-53, 2011.
13. Kaira K, Horie Y, Ayabe E, Murakami H, Takahashi T, Tsuya A, Nakamura Y, Naito T, Endo M, Kondo H, Nakajima T and Yamamoto N: Pulmonary pleomorphic carcinoma: a clinico-pathological study including EGFR mutation analysis. J Thorac Oncol 5: 460-465, 2010.
14. Aketa A, Yamada G, Aketa K, Ohnishi T, Takahashi Y, Kudoh K, Tanaka S, Shiratori M, Takahashi H, Watanabe A, Satoh M and Abe S: Two younger male patients with rapidly progressing pulmonary pleomorphic carcinoma. Nihon Kokyuki Gakkai Zasshi 42: 164-169, 2004 (in Japanese).
15. Bae HM, Min HS, Lee SH, Kim DW, Chung DH, Lee JS, Kim YW and Heo DS: Palliative chemotherapy for pulmonary pleomorphic carcinoma. Lung Cancer 58: 112-115, 2007. (Pubitemid 47379968)
16. Nakamura S, Horiuchi N, Katsura D, Shichijo K, Yoshida S, Harada E, Matsushita T, Oshima Y, Matsuzaki Y, Tamaki Y, Kimura S, Takeichi T, Fujimoto H, Masuda K, Iwasaka N and Shinomiya S: A long-surviving patient with lung pleomorphic carcinoma treated with postoperative carboplatin and paclitaxel combination chemotherapy. Gan To Kagaku Ryoho 35: 965-968, 2008 (in Japanese).
17. Attanoos R, Papagiannis A, Suttinont P, Goddard H, Papotti M and Gibbs A: Pulmonary giant cell carcinoma: pathological entity or morphological phenotype? Histopathology 32: 225-231, 1998.
18. Pelosi G, Rossi G, Bianchi F, Maisonneuve P, Galetta D, Sonzogni A, Veronesi G, Spaggiari L, Papotti M, Barbareschi M, Graziano P, Decensi A, Cavazza A and Viale G: Immunohistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer Eefectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. J Thorac Oncol 6: 1039-1049, 2011.
19. Pelosi G, Fabbri A, Bianchi F, Maisonneuve P, Rossi G, Barbareschi M, Graziano P, Cavazza A, Rekhtman N, Pastorino U, Scanagatta P and Papotti M: Δ(delta)Np63 (p40) and thyroid transcription factor-1 (TTF1) immunoreactivity upon small biopsies or cellblocks for typing non-small cell lung cancer: A novel two-hit, sparing-material approach. J Thorac Oncol 7: 281-290, 2012.
20. Pelosi G, Pasini F, Olsen Stenholm C, Pastorino U, Maisonneuve P, Sonzogni A, Maffini F, Pruneri G, Fraggetta F, Cavallon A, Roz E, Iannucci A, Bresaola E and Viale G: p63 immunoreactivity in lung cancer: Yet another player in the development of squamous cell carcinomas? J Pathol 198: 100-109, 2002. (Pubitemid 34966213)
21. Wang BY, Gil J, Kaufman D, Gan L, Kohtz DS and Burstein DE: P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. Hum Pathol 33: 921-926, 2002.
22. Mukhopadhyay S and Katzenstein AL: Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 35: 15-25, 2011.
23. Rossi G, Papotti M, Barbareschi M, Graziano P and Pelosi G: Morphology and a limited number of immunohistochemical markers may efficiently subtype non-small-cell lung cancer. J Clin Oncol 27: e141-142; author reply e143-144, 2009.
24. Terry J, Leung S, Laskin J, Leslie KO, Gown AM and Ionescu DN: Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 34: 1805-1811, 2010.
25. Travis WD and Rekhtman N: Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Semin Respir Crit Care Med 32: 22-31, 2011.
26. Iwasaki T, Ohta M and Kawahara K: Pulmonary pleomorphic carcinoma: diagnosis using small biopsy specimens. J Thorac Oncol 5: 1492, 2010.
27. Ito K, Oizumi S, Fukumoto S, Harada M, Ishida T, Fujita Y, Harada T, Kojima T, Yokouchi H and Nishimura M: Clinical characteristics of pleomorphic carcinoma of the lung. Lung Cancer 68: 204-210, 2010.
28. Rossi G, Marchioni A, Milani M, Scotti R, Foroni M, Cesinaro A, Longo L, Migaldi M and Cavazza A: TTF-1, cytokeratin 7, 34betaE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung. Am J Clin Pathol 122: 884-893, 2004. (Pubitemid 39577356)
29. Finley JL, Silverman JF and Dabbs DJ: Fine-needle aspiration cytology of pulmonary carcinosarcoma with immunocytochemical and ultrastructural observations. Diagn Cytopathol 4: 239-243, 1988.
30. Hummel P, Cangiarella JF, Cohen JM, Yang G, Waisman J and Chhieng DC: Transthoracic fine-needle aspiration biopsy of pulmonary spindle cell and mesenchymal lesions: a study of 61 cases. Cancer 93: 187-198, 2001. (Pubitemid 32552841)
31. Zafar N and Johns CD: Pleomorphic (sarcomatoid) carcinoma of lung - cytohistologic and immunohistochemical features. Diagn Cytopathol 39: 115-116, 2011.
32. Loo PS, Thomas SC, Nicolson MC, Fyfe MN and Kerr KM: Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 5: 442-447, 2010.
33. Sigel C, Moreira A, Travis W, Zakowski M, Thornton R, Riely G and Rekhtman N: Subtyping of non-small cell lung carcinoma: A comparison of small biopsy and cytology specimens. J Thorac Oncol 6: 1849-1856, 2011.
34. Xu X, Sun PL, Li JZ, Jheon S, Lee CT and Chung JH: Aberrant WNT1/beta-catenin expression is an independent poor prognostic marker of non-small cell lung cancer after surgery. J Thorac Oncol 6: 716-724, 2011.
35. Prudkin L, Liu DD, Ozburn NC, Sun M, Behrens C, Tang X, Brown KC, Bekele BN, Moran C and Wistuba, II: Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol 22: 668-678, 2009.
36. Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, Weder W, Moch H and Kristiansen G: Prognostic significance of epithelial mesenchymal and mesenchymal epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res 14: 7430-7437, 2008.
37. Pelosi G, Pasini F, Fraggetta F, Pastorino U, Iannucci A, Maisonneuve P, Arrigoni G, De Manzoni G, Bresaola E and Viale G: Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids. Lung Cancer 42: 203-213, 2003. (Pubitemid 37268031)
38. Painter JT, Clayton NP and Herbert RA: Useful immunohistochemical markers of tumor differentiation. Toxicol Pathol 38: 131-141, 2010.
39. Facchetti F, Lonardi S, Gentili F, Bercich L, Falchetti M, Tardanico R, Baronchelli C, Lucini L, Santin A and Murer B: Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows Arch 451: 669-680, 2007. (Pubitemid 47340982)
40. Righi L, Graziano P, Fornari A, Rossi G, Barbareschi M, Cavazza A, Pelosi G, Scagliotti GV and Papotti M: Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: A retrospective study of 103 cases with surgical correlation. Cancer 117: 3416-3423, 2011.
41. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, Calabro E, Pastorino U and Sozzi G: Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 106: 16281-16286, 2009.